产品
编 号：F456691
分子式：C7H15N2O4P
分子量：222.18
分子式：C7H15N2O4P
分子量：222.18
产品类型
规格
价格
是否有货
5mg
询价
询价
结构图
CAS No: 777075-44-2
产品详情
生物活性：
cis-ACCP is an orally active antimetastatic matrix metalloproteinase-2 (MMP-2) selective inhibitor. cis-ACCP can inhibit MMP-2 and MMP-9 with IC50 values of 4 μM and 20 μM, respectively. cis-ACCP can be used for the research of a variety of chronic diseases.
体内研究：
cis-ACCP（i.p.；50、250、500 mg/kg；每天一次，持续两周）没有显示出毒性作用并减少小鼠转移形成。cis-ACCP（口服，i.v.，i.p.；50、150 mg/kg）仅分布在细胞外液中。Animal Model:C57BL mice
Dosage:50, 250, 500 mg/kg; 12.5 to 50 mg/kg
Administration:Oral, intraperitoneal, daily for two weeks; daily, 21 days
Result:Showed no toxic effects and showed 50-85% inhibition of metastasis formation, depending on the dose.
Animal Model:Rats
Dosage:50, 150 mg/kg
Administration:Oral, intravenous, intraperitoneal
Result: Showed 84% of the intravenously administered drug are excreted unchanged.
体外研究：
cis-ACCP 可以抑制 MMP-2 和 MMP-9，IC50 值分别为 4 μM 和 20 μM。
cis-ACCP is an orally active antimetastatic matrix metalloproteinase-2 (MMP-2) selective inhibitor. cis-ACCP can inhibit MMP-2 and MMP-9 with IC50 values of 4 μM and 20 μM, respectively. cis-ACCP can be used for the research of a variety of chronic diseases.
体内研究：
cis-ACCP（i.p.；50、250、500 mg/kg；每天一次，持续两周）没有显示出毒性作用并减少小鼠转移形成。cis-ACCP（口服，i.v.，i.p.；50、150 mg/kg）仅分布在细胞外液中。Animal Model:C57BL mice
Dosage:50, 250, 500 mg/kg; 12.5 to 50 mg/kg
Administration:Oral, intraperitoneal, daily for two weeks; daily, 21 days
Result:Showed no toxic effects and showed 50-85% inhibition of metastasis formation, depending on the dose.
Animal Model:Rats
Dosage:50, 150 mg/kg
Administration:Oral, intravenous, intraperitoneal
Result: Showed 84% of the intravenously administered drug are excreted unchanged.
体外研究：
cis-ACCP 可以抑制 MMP-2 和 MMP-9，IC50 值分别为 4 μM 和 20 μM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备